Pharma Wholesale and Distribution Market Forecasts 2016-2026

LONDON, September 16, 2016 /PRNewswire/ --

Prospects for Companies in Original-Branded and Generic Drug Distribution; Profiles, Performance and Revenue Forecasting of Leading Wholesalers in the US, Europe, Japan and China, including McKesson, Cardinal Health, AmerisourceBergen, Walgreens Boots Alliance, MEDIPAL, PHOENIX Group, SINOPHARM and Suzuken 

Report Details  

Pharma Wholesaling and Distribution - Analysis of Companies, Trends and Future Revenues to Benefit Your Influence
What does the future hold for drug wholesale and distribution (W&D) services? Discover revenue predictions there to 2026. And explore trends in those services and technologies, assessing prospects and finding opportunities to benefit your work and authority.

In visiongain's new report you gain revenue forecasts at overall world market, submarket, company and national level. There you assess potentials for expanding revenues. See where that industry's best prospects lie.

Please read on to explore activities of distributors and wholesalers of pharmaceuticals, discovering what that business's future could be worth.

Forecasts and other analysis to benefit your knowledge of medical distribution systems
Is finding pharma wholesale and distribution information a challenge? Avoid falling behind in knowledge on the supply of medicines. With our data, help your research, analyses and decisions. Also save time and benefit your reputation for commercial insight.

Besides revenue forecasting, our new investigation shows historical data, growth rates and market shares. That industry changes in 2016 through mergers and acquisitions. In our study discover what is happening, helping you stay ahead.

There you find original quantitative and qualitative analyses, exploring business outlooks and developments. In our 272 page study you gain 83 tables, 98 charts and a research interview.

Discover where revenues can increase most. In the following sections you see how our new study benefits your knowledge on the supply chain for human medicines.

To see a report overview please email Sara Peerun on [email protected]

Prospects for that world market and submarkets - discover what revenues are possible
Our new report shows revenue to 2026 for the overall world market. It also gives you forecasts for three submarkets in the distributing and wholesaling of medicines:
• Original-branded pharmaceuticals - small molecules and biological drugs
• Generic prescription medicines - generics
• Other products related to pharmaceutical supply.

Discover pharma distribution chain revenues. How will that wholesaling and distributing market grow? Which parts will prosper most, and why? With our data you assess potential sales and revenue growth. See what is possible from 2016.

In our study you also discover geographical revenue predictions.

Sales potentials for medical wholesaling and distributing in leading countries
Developments worldwide expand the pharma W&D market, especially rising demand for medicines in fast-emerging countries. China, India, Russia and Brazil underpin revenue growth. Discover how domestic and international suppliers expand business.

In developed and developing regions opportunities for drug wholesalers and other medical suppliers will occur from 2016. Pharmacies also stand to gain. See where, why and how, discovering what is possible.

Our report shows you individual revenue forecasts to 2026 for 11 national markets:
• United States
• Japan
• Germany, France, United Kingdom, Italy and Spain (EU5)
• Brazil, Russia, India and China (BRIC).

There you discover progress and outlooks. You assess the W&D industry's future, seeing developments and finding their meaning.

Forecasting and other analyses for leading pharma supply chain intermediaries
How will prominent W&D companies perform to 2026? Our work shows you individual revenue forecasts for 10 leading pharma wholesalers and distributors:
• McKesson
• Cardinal Health
• AmerisourceBergen
• Walgreens Boots Alliance
• MEDIPAL HOLDINGS
• The PHOENIX Group
• SINOPHARM
• Alfresa Holdings
• Suzuken
• Shanghai Pharmaceutical Holdings.

With our sales predictions you assess organisations, seeing activities, results, changes and outlooks. You find what is happening, exploring trends, competition, challenges and opportunities.

That way you investigate the pharma W&D industry's prospects, discovering progress and finding what it means. Our study explains the issues affecting that industry's present and future.

Forces and changes affecting the supply of medicines through distribution networks
Our report explains issues, events and shifts affecting that industry and market from 2016, including these influences:
• Roles of pharmaceutical wholesalers - activities, changes and prospects
• Revenues, costs and profits - find results, opportunities and sales potentials
• Direct-to-pharmacy (DTP) activities - assess how those developments affect suppliers, clients and the W&D market
• Full-line wholesalers (FLWs), short-line wholesalers (SLWs) and the drug distribution chain, including logistical service providers
• Technologies and services - progress in supplying pharmacies, clinics and hospitals, serving healthcare professionals, governments, payers and patients
• Forward buying, fee-for-service systems and the rise of retail pharmacies.

Our investigation also discusses other aspects of that industry, including these forces:
• Alliance Boots merging with Walgreens, McKesson's acquisition of Celesio and other consolidation - explore deals changing that industry
• Parallel trade - activities, policies, challenges and effects
• Inventory management agreements, clawback, reimbursement and discounts
• Rise of specialty medicines, including biologics, vaccines and biosimilars - opportunities for intermediaries, including cold chain distribution networks
• Actions against drug counterfeiting - security of pharmaceutical supply chains
• Changes to regulations and healthcare budgets - policies affecting trade.

That way you assess technological, economic, social and political questions, exploring news and outlooks for the medical supply chain. You also analyse that industry's strengths, weaknesses, opportunities and threats. See what the future holds.

Value of the overall pharma W&D market in 2020 - what revenue is possible?
Visiongain forecasts that the overall pharmaceutical wholesale and distribution industry will achieve revenue of $1,357 billion worldwide in 2020. That market will rise further - see what gains are possible.

Wholesaling and distributing services will experience steady revenue growth from 2016 to 2026, adapting to driving and restraining forces - changes, opportunities and threats. Find how high that industry's turnover can go, also exploring what influences its revenues and profits.

So discover, with our data, revenue streams and opportunities for intermediaries in the pharma supply chain. There you explore established and rising companies. Their market holds great potential from 2016 for investments, progress and expansion.

6 main ways Pharma Wholesale and Distribution Market Forecasts 2016-2026 helps
In our new analysis you gain the following knowledge to benefit your analyses, plans, presentations and authority:
• World pharma W&D revenue to 2026 - discover that industry's overall sales potential from 2016
• 3 world-level submarkets' revenues to 2026 - investigate potentials, finding the most promising segments for developments, investments and sales
• 10 top companies' revenues to 2026 - discover forecasts for leading players, seeing how they develop their businesses, compete and succeed
• 11 national market forecasts to 2026 in the Americas, Europe and Asia - explore top countries for revenues, demand and potential sales expansion
• Activities of leading organisations - analyse participants' financial results, strategies, capacities, partnerships, mergers and acquisitions
• Competition and opportunities - explore what shapes that industry's future, assessing prospects for sustaining and developing business.

That report, by visiongain's in-house analysts in the UK, gives knowledge with the purpose of saving you effort and time, making your work easier and more likely to succeed. You gain analysis leading companies depend on.

Data found nowhere else - benefit your research, decisions, plans and influence
Our investigation gives independent analysis. There you receive discussions and predictions found only in our report, seeing where prospects are most rewarding.

With our study you are less likely to fall behind in knowledge or miss opportunity. Discover there how you could benefit your research, analyses, plans and decisions, also saving time and getting recognition for commercial insight.

Our analysis costs only a tiny fraction of potential profits from your exploring and harnessing the pharma W&D market. Assess its changes and growth potentials.

Forecasts for pharmaceutical supply - stay ahead by trying our analysis now
Our new study is for everyone analysing the supply of human medicines. In that work you explore results, trends, opportunities and revenue predictions, seeing what is possible. Avoid missing out. Stay ahead by getting our report here now.

To see a report overview please email Sara Peerun on [email protected]

To request a report overview of this report please emails Sara Peerun at [email protected] or call Tel: +44 (0) 20 7336 6100

Or click on https://www.visiongain.com/Report/1721/Pharma-Wholesale-and-Distribution-Market-Forecasts-2016-2026

Organisations Mentioned in the Report 

36.6 Group

AAH Pharmaceuticals

AccessClosure

ACM (Authority for Consumers & Markets)

ADG Apotheken-Dienstleistungsgesellschaft mbH

Admenta Italia

Alfresa Corporation

Alfresa Healthcare Corporation

Alfresa Holdings

Alfresa Medical Service Corporation

Alfresa Nikken Sangyo Corporation

Alfresa Pharma Corporation

Alfresa System Corporation

Alliance Boots

Alliance Healthcare

Alphega Network

AmerisourceBergen

Apokjeden AS

Apollo Medical Holdings

ARATA CORPORATION

Asociación Cooperativas Farmacéuticas (Acofarma)

AssuraMed

ASTIS Co.

AstraZeneca

Athos Farma

Barr Pharmaceuticals

Bayer

Biologics Inc

Bristol-Myers Squibb

Brocacef Groep NV

Bundesverband des PharmazeutischenGrosshandel (PHAGRO)

Cardinal Foods

Cardinal Health

Cardinal Health China

CareFusion

Catalent Pharma Solutions

Celesio AG

Celesio UK

CERP BretagneNord

CERP Network

CERP Rouen

China Health Systems

China National Pharmaceutical Group

Chuo Unyu Co.

Cofares

Comifar

Comifar Group

Cordis

CS YAKUHIN CO.

CVS Caremark

Daiichi Sankyo Propharma Co

DEA

Dong Ying (Jiangsu) Pharmaceuticals Co.

DrogariasTamoio Network

Drug Trading Company

Emart Company

ERP Rhin Rhone Mediterranee

European Association of Euro-Pharmaceutical Companies (EAEPC)

European Court of Justice

European Pharmacy Network (EPN)

Express Scripts

Food and Drug Administration (US FDA)

Gilead Sciences

GlaxoSmithKline (GSK)

Guangzhou Pharmaceutical Company

Guangzhou Pharmaceuticals Corporation (GP Corp)

Hanshin Dispensing Pharmacy Holdings Co.

Harvard Drug

Healthcare Solutions Holding

Hefame

Institute for Pharmaeconomic Research (IPF)

Japanese Pharmaceutical Wholesalers Association

Johnson & Johnson

Katz Group

Kenzmedico Co.

Kinray

Kowa Pharmaceuticals Co.

Libra AG

Life Medicom Co.

LloydsPharmacy

McKesson

McQueary Brothers of Springfield

Medicaid

Medicare

Medicine Shoppe Canada

Medipal Holdings

Mediq Apotheken Nederland B.V.

Meisho Co.

Metro Medical Supply

MSD

Nakano Yakuhin Co.

National Development and Reform Commission (NDRC)

National Health Insurance (NHI)

National Health Service (NHS)

National Pharmaceutical Pricing Authority (NPPA)

NaviHealth

Nihon Apoch Co

Nomeco

Novation LLC

Novodata Zrt

Odashima Limited

Oncology Therapeutics

Oncoprod

Outcomes Incorporated

P.JD. Network

Panpharma

Pfercos Co.

Pfizer

PharMEDium Healthcare Holdings

PHOENIX Arzneiwarengroßhandlung Ges.m.b.H.

PHOENIX Farmacija d.d.

PHOENIX Group

PHOENIX Lékárenský velkoobchod, a.s.

PHOENIX Pharma d.o.o.

PHOENIX Pharma DOOEL

PHOENIX Pharma Polska Sp. z o.o.

PHOENIX Pharma S.A.S

PHOENIX Pharma Zrt.

PHOENIX Pharmahandel

PHOENIX Zdravotnícke zásobovanie

Polish Pharmaceutical Council (NRA)

Polska Grupa Farmaceutyczna, Torfarm

Premium Purchasing Partners LP

Profarma

Prosper

Protek

PSS World Medical

QINGDAO NESCO MEDICAL CO.

Raintree Oncology Services

Ratiopharm

Red Oak

Rexall Health

RYUYAKU CO.

S.D.Next Co.

Sanacorp

Sandoz

Sanki Clinical Link Co.

Sanki Corporation

Sanki MediHeart Limited

Sanki Wellbe Co., Ltd. S-Care Mate Co.

Sanofi

Sanwa Kagaku Kenkyusho Co.

Sciclone Trade

SEIWA SANGYO CO.

Shanghai Pharmaceuticals

Shikoku Alfresa Corporation

Shinsegai Group

Shoyaku Co.

SIA International

SIA Tamro

SINOPHARM Group Co.

Sonexus Health

St. Francis Group

State Food and Drug Administration (SFDA)

SUNPHARMA

SUZUKEN

Suzuken Iwate Co.

Suzuken Okinawa Yakuhin Co.

TAMPEI NAKATA CO.

Tamro AB

Tamro Eesti OÜ

Tamro Oyj

The Healthcare Distribution Management Association (HDMA)

Tokiwa Yakuhin Co

Tradex International

UAB Tamro

US Oncology Holdings

Vantage Oncology

Walgreens

Walmart

World Courier Group

Wuhan Chopper Biology

Zuellig Pharma China

To see a report overview please email Sara Peerun on [email protected]

SOURCE Visiongain Ltd